El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigation

Medical Entomology

Research Lines

Content with Investigacion Referencia e Investigación en Helmintos .

Referencia e Investigación en Helmintos

null

Research projects

Content with Investigacion Referencia e Investigación en Helmintos .

PROYECTOS VIGENTES

Título del proyecto: "Vesículas extracelulares y otras moléculas de parásitos para el tratamiento de la enfermedad inflamatoria intestinal: PARATREAT-IBD"

Referencia: Proyecto PID2022-137661OB-I00 (MPY 341/23) financiado por MCIN/AEI /10.13039/501100011033/ y por FEDER Una manera de hacer Europa
Fecha Inicio:    01/12/2023
Fecha Fin:    31/08/2026
Financiación: 162.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Agencia Estatal de Investigación. MICINN.


 

Título del proyecto: "Desarrollo de nuevos métodos diagnósticos y de seguimiento de la infección por schistosoma haematobium"

Referencia: PI23CIII00034 / MPY 386/23
Fecha Inicio:    01/01/2024
Fecha Fin:    31/12/2026
Financiación: 131.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)

 

Título del proyecto: "Desarrollo de herramientas para el control de la teniosis / cisticercosis en zonas endémicas y vigilancia de las helmintosis humanas emergentes en España"

Referencia: PI22CIII/00010
Fecha Inicio: 01/01/2023
Fecha Fin: 31/12/2025
Financiación: 80.000 Euros
Investigador principal: María Jesús Perteguer
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)

 

 

PROYECTOS PASADOS

Título del proyecto: "PERITAS: Molecular epidemiological studies on pathways of transmission and longlasting capacity building to prevent cystic echinococcosis infection."
Coordinador: Adriano Casulli. IP of ISCIII: Maria J. Perteguer.
Entidad financiadora: EULAC Health JOINT CALL on Research and Innovation 016-2017
Periodo: 01/03/2019-31/12/2022.
Cuantía total: 1.083.580 €.

Título del proyecto: "Producción de antígenos y controles positivos recombinantes para el desarrollo y la estandarización de nuevos ensayos serológicos aplicados al diagnóstico y control de helmintosis olvidadas. "
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 02/11/2018 - 31/06/2022.
Cuantía total: 78.050 €.

Título del proyecto: "Diagnóstico serológico diferencial de helmintiasis asociadas a eosinofilia: desarrollo de ensayos multianalito (xMAP) con antígenos recombinantes de especies de interés clínico"
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 01/01/2015 - 31/12/2018 .
Cuantía total: 91.000 €.

Search Bar

Publications

Sort
Category

Cervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS.

Nebreda T, Andres AG, Fuentes S, Calleja R, Jimenez MS. Cervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS. New Microbes and New Infections .2018. March 22:1-3.

PUBMED DOI

In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain.

Sagasta S, Millan-Lou MI, Jiménez MS, Martin C, Samper S. In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis. 2016. Sep. 100:46-52.

PUBMED DOI

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.

Battles MB, Mas V, Olmedillas E, Cano O, Vazquez M, Rodriguez L, et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat Commun. 2017;8(1):1528.

PUBMED DOI

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60(1):6-13.

PUBMED DOI

Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin

Garcia-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, et al. Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol. 2014;95(Pt 5):1033-42.

PUBMED DOI

Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.

Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Tato Marinho R, Borrego P, Taveira N. 2018. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8:12266. (A; FI= 4.12; Q1 Multidisciplinary Sciences; DOI:10.1038/s41598-018-30528-0).

PUBMED DOI

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.

Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Morón S, Jiménez-Sousa MA, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep. 2017; 7(1):2892. (A; FI= 4.12; Q1 Multidisciplinary Sciences).

PUBMED DOI

Plasma miRNA profile at COVID-19 onset predicts severity status and mortality.

Fernández-Pato A; Virseda-Berdices A, Ryan P; Martínez-González O, Peréz-García F, Resino S, Martin-Vicente M, Valle-Millares D, Brochado-Kith O; Blancas R; Ceballos FC; Bartolome-Sánchez S; Vidal-Alcántara EJ; Alonso-Menchén D, Blanca-López N; Ramirez Martinez-Acitores I, Rava M, Jiménez-Sousa MA (‡ *), Amanda Fernández-Rodríguez (‡ *). Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect 2022; 11(1):676-688 (A; FI= 19.57; D1, Infectious Diseases; JCR 2021).

PUBMED DOI

Content with Investigacion Referencia e Investigación en Helmintos .

List of staff

Additional Information

The Medical Entomology Laboratory has accumulated extensive experience in this field, especially in entomological field studies, biology of arthropods of medical interest, vector competence and vector control. Also, in the molecular detection of Leishmania infantum promastigotes in naturally parasitized phlebotomine sand flies, in the molecular identification of blood ingested by hematophagous arthropods and in the study of the immunomodulatory properties of proteins present in the saliva of phlebotomine sand flies and mosquitoes. Our laboratory is currently co-leading the studies of vectors and wild reservoirs of leishmaniasis in the leishmaniasis focus of Fuenlabrada, Madrid. In this sense, we have studied the role of asymptomatic individuals as reservoirs in the outbreak by xenodiagnosis. On the other hand, we have participated since 2007 in the Entomological Surveillance Program in Airports and Ports against Potential Vectors of Exotic Infectious Diseases, a program that is allowing to develop the expansion map in Spain of Aedes albopictus. In 2016-2017, we carried out surveillance of Ae. albopictus in the Community of Castilla-La Mancha. On the other hand, we conducted studies on the role of patients with post-kala-azar dermal leishmaniasis (PKDL) in the transmission of the parasite in Bangladesh and Sudan. In addition, we participate in research studying ticks transmitting Crimean-Congo hemorrhagic fever in Spain.

Currently, it maintains confidentiality agreements with several companies participating in the evaluation of molecules with activity against pathogens in vectors (GSK), in the development of vector traps using artificial intelligence algorithms (Irideon, Spain), and in the evaluation of repellents against phlebotomine sand flies (IRSEA, France).

The laboratory actively participates in outreach activities such as the Science Week or the European Researchers' Night, among others, making medical entomology science available to the general population.

The Medical Entomology Laboratory has accumulated extensive experience in this field, especially in entomological field studies, biology of arthropods of medical interest, vector competence and vector control. Also, in the molecular detection of Leishmania infantum promastigotes in naturally parasitized phlebotomine sand flies, in the molecular identification of blood ingested by hematophagous arthropods and in the study of the immunomodulatory properties of proteins present in the saliva of phlebotomine sand flies and mosquitoes. Our laboratory is currently co-leading the studies of vectors and wild reservoirs of leishmaniasis in the leishmaniasis focus of Fuenlabrada, Madrid. In this sense, we have studied the role of asymptomatic individuals as reservoirs in the outbreak by xenodiagnosis. On the other hand, we have participated since 2007 in the Entomological Surveillance Program in Airports and Ports against Potential Vectors of Exotic Infectious Diseases, a program that is allowing to develop the expansion map in Spain of Aedes albopictus. In 2016-2017, we carried out surveillance of Ae. albopictus in the Community of Castilla-La Mancha. On the other hand, we conducted studies on the role of patients with post-kala-azar dermal leishmaniasis (PKDL) in the transmission of the parasite in Bangladesh and Sudan. In addition, we participate in research studying ticks transmitting Crimean-Congo hemorrhagic fever in Spain.

Currently, it maintains confidentiality agreements with several companies participating in the evaluation of molecules with activity against pathogens in vectors (GSK), in the development of vector traps using artificial intelligence algorithms (Irideon, Spain), and in the evaluation of repellents against phlebotomine sand flies (IRSEA, France).

The laboratory actively participates in outreach activities such as the Science Week or the European Researchers' Night, among others, making medical entomology science available to the general population.

Content with Investigacion Referencia e Investigación en Helmintos .